title: The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
abstract: Glanzmann's thrombasthenia (GT) is characterized by increased bleeding risk. The treatment options in GT are limited. The aim of this study was to test the effect of GT blood supplementation with fibrinogen and factor XIII on thrombin generation, blood clotting, and fibrinolysis. Whole blood samples of GT patients and normal donors treated with eptifibatide (GT model) were subjected to clotting by CaCl(2) and tissue factor. Thrombin generation was measured in platelet-rich plasma. Clot formation and tPA-induced fibrinolysis were evaluated in whole blood by rotation thromboelastometry (ROTEM). Blood was supplemented with fibrinogen (3 g/L) and/or FXIII (2 IU/mL). Thrombin generation analysis of blood derived from GT model and GT patients revealed decreased endogenous thrombin potential and peak height and extended lag time compared to control. However, this method was not sensitive to blood spiking with fibrinogen and FXIII. ROTEM revealed lower maximum clot firmness (MCF) and area under curve (AUC) in the blood of GT model and GT patients. In the absence of exogenous tPA, blood spiking with fibrinogen markedly enhanced clot quality while FXIII had no effect. Combination of fibrinogen and FXIII did not add to the effect of fibrinogen. In contrast, by the addition of tPA, both fibrinogen and FXIII separately and, to more extent, in combination enhanced clot quality as well as resistance against tPA-induced fibrinolysis (increasing MCF, AUC, and lysis onset time). In conclusion, fibrinogen and FXIII exerted stimulation of blood clotting and inhibition of fibrinolysis. Treating normal blood with eptifibatide mimics the changes of coagulopathy in GT blood.
authors.affiliation: Institute of Thrombosis & Hemostasis and the National Hemophilia Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel. borshenk@sheba.health.gov.il
authors.forename: Boris
authors.initials: B
authors.lastname: Shenkman
authors.forename: Tami
authors.initials: T
authors.lastname: Livnat
authors.forename: Mudi
authors.initials: M
authors.lastname: Misgav
authors.forename: Ivan
authors.initials: I
authors.lastname: Budnik
authors.forename: Yulia
authors.initials: Y
authors.lastname: Einav
authors.forename: Uriel
authors.initials: U
authors.lastname: Martinowitz
mesh_terms: D019540:Area Under Curve; D001777:Blood Coagulation / Q000187:drug effects*; D002122:Calcium Chloride / Q000494:pharmacology; D016022:Case-Control Studies; D000077542:Eptifibatide; D005176:Factor XIII / Q000494:pharmacology*; D005340:Fibrinogen / Q000494:pharmacology*; D006801:Humans; D010455:Peptides / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D053657:Platelet-Rich Plasma / Q000737:chemistry; D013915:Thrombasthenia / Q000097:blood*; D013916:Thrombelastography; D013917:Thrombin / Q000819:agonists / Q000378:metabolism*; D013918:Thrombin Time; D013925:Thromboplastin / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000494:pharmacology
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D005340:Fibrinogen; D005176:Factor XIII; D013925:Thromboplastin; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D002122:Calcium Chloride; D000077542:Eptifibatide